{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:52:25Z","timestamp":1792511545836,"version":"4.5.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clbc.2024.12.016","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T12:35:02Z","timestamp":1735648502000},"page":"e403-e418.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identification and Management of Medical Comorbidities in Patients With HR+\/HER2\u2013 Metastatic Breast Cancer Treated With CDK4\/6 Inhibitors: Literature Review and Recommendations From Experts in Spain Opinion"],"prefix":"10.1016","volume":"25","author":[{"given":"Carmen","family":"Hinojo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Cantos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Antol\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Arqueros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"D\u00edaz-Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iria","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisenda","family":"Llabr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Alonso","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Barral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreto","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Juan","family":"Linares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge V.","family":"L\u00f3pez-Ibor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidy","family":"Campo Palacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Piedra Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"de la Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2024.12.016_bib0001","unstructured":"REDECAN. Estimaciones de la incidencia del c\u00e1ncer en Espa\u00f1a, 2024. Published online 2024. Accessed June 30, 2024. https:\/\/redecan.org\/storage\/documents\/09a96a55-6939-419d-ba3e-202d7ae76e1d.pdf."},{"issue":"4","key":"10.1016\/j.clbc.2024.12.016_bib0002","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.18632\/aging.202502","article-title":"Global incidence and mortality of breast cancer: a trend analysis","volume":"13","author":"Huang","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"5","key":"10.1016\/j.clbc.2024.12.016_bib0003","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"10.1016\/j.clbc.2024.12.016_bib0004","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clbc.2024.12.016_bib0005","first-page":"e23901","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors: a quantum leap in the treatment of advanced breast cancers","volume":"14","author":"Reddy","year":"2022","journal-title":"Cureus"},{"issue":"25","key":"10.1016\/j.clbc.2024.12.016_bib0006","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2024.12.016_bib0007","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1007\/s12094-023-03203-8","article-title":"SEOM\u2013GEICAM\u2013SOLTI clinical guidelines in advanced breast cancer (2022)","volume":"25","author":"Garcia-Saenz","year":"2023","journal-title":"Clin Transl Oncol"},{"issue":"14","key":"10.1016\/j.clbc.2024.12.016_bib0008","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/jnci\/djr188","article-title":"The influence of comorbidities on overall survival among older women diagnosed with breast cancer","volume":"103","author":"Patnaik","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.clbc.2024.12.016_bib0009","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/j.clon.2019.05.003","article-title":"Generalisability of common oncology clinical trial eligibility criteria in the real world","volume":"31","author":"Karim","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.clbc.2024.12.016_bib0010","article-title":"Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR(+)\/HER2(-) breast cancer treated with CDK4\/6 inhibitors and endocrine therapy","volume":"12","author":"Tagliaferri","year":"2023","journal-title":"Drugs Context"},{"key":"10.1016\/j.clbc.2024.12.016_bib0011","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.breast.2020.10.005","article-title":"Eligibility of real-world patients with metastatic breast cancer for clinical trials","volume":"54","author":"Batra","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2024.12.016_bib0012","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.breast.2021.08.005","article-title":"Population-based recurrence rates among older women with HR-positive, HER2-negative early breast cancer: clinical risk factors, frailty status, and differences by race","volume":"59","author":"Zhou","year":"2021","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.clbc.2024.12.016_bib0013","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s10549-010-0732-3","article-title":"Medical comorbidities predict mortality in women with a history of early stage breast cancer","volume":"122","author":"Patterson","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2024.12.016_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.897951","article-title":"An integrated pharmacological counselling approach to guide decision-making in the treatment with CDK4\/6 inhibitors for metastatic breast cancer","volume":"13","author":"Roncato","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clbc.2024.12.016_bib0015","unstructured":"The top 10 causes of death. Accessed June 30, 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death."},{"issue":"2","key":"10.1016\/j.clbc.2024.12.016_bib0016","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1016\/j.clbc.2018.12.005","article-title":"Impact of baseline cardiovascular comorbidity on outcomes in women with breast cancer: a real-world, population-based study","volume":"19","author":"Abdel-Rahman","year":"2019","journal-title":"Clin Breast Cancer"},{"issue":"8","key":"10.1016\/j.clbc.2024.12.016_bib0017","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","article-title":"Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the american heart association","volume":"137","author":"Mehta","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.016_bib0018","article-title":"Cardiovascular disease among breast cancer survivors","volume":"2","author":"Coughlin","year":"2020","journal-title":"Cardiovasc Disord Med"},{"issue":"9","key":"10.1016\/j.clbc.2024.12.016_bib0019","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cncr.28509","article-title":"Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer","volume":"120","author":"Edwards","year":"2014","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2024.12.016_bib0095","first-page":"160","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"72","year":"2019","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"2","key":"10.1016\/j.clbc.2024.12.016_bib0020","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/20009666.2020.1726571","article-title":"Atrial fibrillation and cancer; understanding the mysterious relationship through a systematic review","volume":"10","author":"Lateef","year":"2020","journal-title":"J community Hosp Intern Med Perspect"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.016_bib0021","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1186\/s12885-019-6314-9","article-title":"Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population-based 12\u2009year follow up study","volume":"19","author":"Jakobsen","year":"2019","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.clbc.2024.12.016_bib0022","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the Europe","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.016_bib0023","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1186\/s12885-017-3719-1","article-title":"Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis","volume":"17","author":"Khan","year":"2017","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.clbc.2024.12.016_bib0024","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.clbc.2024.12.016_bib0025","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO clinical practice guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.clbc.2024.12.016_bib0026","unstructured":"Obesity and overweight. Accessed June 30, 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"issue":"35","key":"10.1016\/j.clbc.2024.12.016_bib0027","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1200\/JCO.2016.68.4480","article-title":"Obesity and breast cancer prognosis: evidence, challenges, and opportunities","volume":"34","author":"Jiralerspong","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.clbc.2024.12.016_bib0028","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2024.12.016_bib0029","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1001\/jamaoncol.2018.0137","article-title":"Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer","volume":"4","author":"Caan","year":"2018","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.clbc.2024.12.016_bib0030","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11912-016-0546-5","article-title":"Clinical implications of sarcopenic obesity in cancer","volume":"18","author":"Carneiro","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clbc.2024.12.016_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2020.101710","article-title":"Impact of preexisting type 2 diabetes mellitus and antidiabetic drugs on all-cause and cause-specific mortality among Medicaid-insured women diagnosed with breast cancer","volume":"66","author":"Lawrence","year":"2020","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"10.1016\/j.clbc.2024.12.016_bib0032","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00125-012-2793-9","article-title":"Incidence of diabetes among postmenopausal breast cancer survivors","volume":"56","author":"Lipscombe","year":"2013","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.clbc.2024.12.016_bib0033","first-page":"e8010","article-title":"Diabetes as a risk factor for breast cancer","volume":"12","author":"Eketunde","year":"2020","journal-title":"Cureus"},{"issue":"9","key":"10.1016\/j.clbc.2024.12.016_bib0034","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1210\/clinem\/dgac375","article-title":"The effects of diabetes and glycemic control on cancer outcomes in individuals with metastatic breast cancer","volume":"107","author":"Cheung","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.clbc.2024.12.016_bib0035","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/0148607113502674","article-title":"Prevalence of malnutrition and current use of nutrition support in patients with cancer","volume":"38","author":"H\u00e9buterne","year":"2014","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1016\/j.clbc.2024.12.016_bib0036","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/601434","article-title":"Cancer cachexia: mechanisms and clinical implications","volume":"2011","author":"Donohoe","year":"2011","journal-title":"Gastroenterol Res Pract"},{"issue":"3","key":"10.1016\/j.clbc.2024.12.016_bib0037","first-page":"1163","article-title":"Meta-analysis of vitamin D sufficiency for improving survival of patients with breast cancer","volume":"34","author":"Mohr","year":"2014","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.016_bib0038","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nutres.2010.12.001","article-title":"Prevalence and correlates of vitamin D deficiency in US adults","volume":"31","author":"Forrest","year":"2011","journal-title":"Nutr Res"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.016_bib0096","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clnu.2016.07.015","article-title":"ESPEN guidelines on nutrition in cancer patients","volume":"36","author":"Arends","year":"2017","journal-title":"Clin Nutr"},{"issue":"Suppl 1","key":"10.1016\/j.clbc.2024.12.016_bib0097","first-page":"S125","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.clbc.2024.12.016_bib0098","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1210\/er.2017-00253","article-title":"The science of obesity management: an endocrine society scientific statement","volume":"39","author":"Bray","year":"2018","journal-title":"Endocr Rev"},{"issue":"3","key":"10.1016\/j.clbc.2024.12.016_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278454","article-title":"Liver function indicators in patients with breast cancer before and after detection of hepatic metastases-a retrospective study","volume":"18","author":"Leser","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2024.12.016_bib0040","unstructured":"Kisqali\u00ae. Technical data sheet of the medication. US Food and Drug Administration (FDA). Accessed November 3, 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/ribociclib-kisqali."},{"key":"10.1016\/j.clbc.2024.12.016_bib0041","unstructured":"Verzenios\u00ae. Technical data sheet of the medication. US Food and Drug Administration (FDA). Accessed November 3, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208716s006s007s008lbl.pdf."},{"key":"10.1016\/j.clbc.2024.12.016_bib0042","unstructured":"Ibrance\u00ae. Technical data sheet of the medication. US Food and Drug Administration (FDA). Accessed November 3, 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/palbociclib-ibrance."},{"key":"10.1016\/j.clbc.2024.12.016_bib0043","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919833867","article-title":"Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication","volume":"11","author":"Bellet","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clbc.2024.12.016_bib0044","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/psb.1800","article-title":"Recommended management of dyspepsia in primary care","volume":"30","author":"Gosson","year":"2019","journal-title":"Prescriber"},{"issue":"4","key":"10.1016\/j.clbc.2024.12.016_bib0045","first-page":"242","article-title":"Relationship between non-alcoholic fatty liver disease and breast cancer","volume":"19","author":"Nseir","year":"2017","journal-title":"Isr Med Assoc J"},{"issue":"8","key":"10.1016\/j.clbc.2024.12.016_bib0046","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso","year":"2011","journal-title":"Ann Med"},{"issue":"8","key":"10.1016\/j.clbc.2024.12.016_bib0047","doi-asserted-by":"crossref","first-page":"e653","DOI":"10.1634\/theoncologist.2018-0370","article-title":"Aromatase inhibitors and newly developed nonalcoholic fatty liver disease in postmenopausal patients with early breast cancer: a propensity score-matched cohort study","volume":"24","author":"Lee","year":"2019","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.clbc.2024.12.016_bib0048","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4048\/jbc.2021.24.e41","article-title":"Fatty liver in hormone receptor-positive breast cancer and its impact on patient's survival","volume":"24","author":"Taroeno-Hariadi","year":"2021","journal-title":"J Breast Cancer"},{"issue":"5","key":"10.1016\/j.clbc.2024.12.016_bib0049","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.gastrohep.2017.12.003","article-title":"Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline","volume":"41","author":"Aller","year":"2018","journal-title":"Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.clbc.2024.12.016_bib0099","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.clbc.2024.12.016_bib0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1471-2458-8-117","article-title":"Prevalence of chronic kidney disease in population-based studies: systematic review","volume":"8","author":"Zhang","year":"2008","journal-title":"BMC Public Health"},{"issue":"11","key":"10.1016\/j.clbc.2024.12.016_bib0051","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.2215\/CJN.11030919","article-title":"Sex and the incidence and prevalence of kidney disease","volume":"14","author":"Tomlinson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.clbc.2024.12.016_bib0052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease - a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2024.12.016_bib0053","unstructured":"NICE. National Institute for Health Care Excellence: Management of chronic kidney disease. Accessed June 30, 2024. https:\/\/www.nice.org.uk\/guidance\/conditions-and-diseases\/kidney-conditions\/chronic-kidney-disease."},{"issue":"10","key":"10.1016\/j.clbc.2024.12.016_bib0054","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1007\/s10147-020-01733-7","article-title":"Why is renal impairment associated with poorer cancer specific survival in breast cancer patients?: a comparison with patients with other comorbidities","volume":"25","author":"Evans","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.016_bib0055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1477-7819-11-77","article-title":"Breast cancer after kidney transplantation: a single institution review","volume":"11","author":"Kwak","year":"2013","journal-title":"World J Surg Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2024.12.016_bib0056","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/S0041-1345(02)03063-4","article-title":"De novo breast cancer in renal transplant recipients","volume":"34","author":"Buell","year":"2002","journal-title":"Transplant Proc"},{"issue":"3","key":"10.1016\/j.clbc.2024.12.016_bib0100","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.nefro.2021.07.010","article-title":"Information and consensus document for the detection and management of chronic kidney disease","volume":"42","author":"Garc\u00eda-Maset","year":"2022","journal-title":"Nefrologia"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.016_bib0057","first-page":"359","article-title":"Comorbidity, cognitive dysfunction, physical functioning, and quality of life in older breast cancer survivors","volume":"30","author":"Crouch","year":"2022","journal-title":"Support care cancer Off J Multinatl Assoc Support Care Cancer"},{"issue":"8","key":"10.1016\/j.clbc.2024.12.016_bib0058","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2165\/11591990-000000000-00000","article-title":"Exclusion of older people from clinical trials: professional views from nine European countries participating in the PREDICT study","volume":"28","author":"Crome","year":"2011","journal-title":"Drugs Aging"},{"issue":"24","key":"10.1016\/j.clbc.2024.12.016_bib0059","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2024.12.016_bib0060","first-page":"1033","article-title":"Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer","volume":"24","author":"Torregrosa-Maicas","year":"2022","journal-title":"Clin Transl Oncol Off Publ Fed Spanish Oncol Soc Natl Cancer Inst Mex"},{"issue":"3","key":"10.1016\/j.clbc.2024.12.016_bib0061","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s12282-019-01040-8","article-title":"Comorbidity and polypharmacy in patients with breast cancer","volume":"27","author":"Topalo\u011flu","year":"2020","journal-title":"Breast Cancer"},{"issue":"9","key":"10.1016\/j.clbc.2024.12.016_bib0062","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/gerona\/glx245","article-title":"Associations of sarcopenia definitions, and their components, with the incidence of recurrent falling and fractures: the longitudinal aging study Amsterdam","volume":"73","author":"Schaap","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.016_bib0063","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/jcsm.12048","article-title":"SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes","volume":"7","author":"Malmstrom","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.clbc.2024.12.016_bib0064","first-page":"861","article-title":"Impact of body composition on outcome in patients with early breast cancer","volume":"26","author":"Deluche","year":"2018","journal-title":"Support care cancer Off J Multinatl Assoc Support Care Cancer"},{"issue":"9","key":"10.1016\/j.clbc.2024.12.016_bib0101","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S1470-2045(14)70018-X","article-title":"Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology","volume":"15","author":"Droz","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2024.12.016_bib0102","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1634\/theoncologist.2016-0462","article-title":"Geriatric assessment predicts survival and competing mortality in elderly patients with early colorectal cancer: can it help in adjuvant therapy decision-making?","volume":"22","author":"Antonio","year":"2017","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.016_bib0103","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"issue":"2","key":"10.1016\/j.clbc.2024.12.016_bib0104","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.berh.2017.11.007","article-title":"Sarcopenia","volume":"31","author":"Fuggle","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.clbc.2024.12.016_bib0105","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.arr.2019.02.005","article-title":"Effect of nutritional supplementations on physical performance and muscle strength parameters in older people: a systematic review and meta-analysis","volume":"51","author":"Veronese","year":"2019","journal-title":"Ageing Res Rev"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.016_bib0106","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.clnu.2018.05.024","article-title":"ESPEN guideline on clinical nutrition and hydration in geriatrics","volume":"38","author":"Volkert","year":"2019","journal-title":"Clin Nutr"},{"key":"10.1016\/j.clbc.2024.12.016_bib0107","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.freeradbiomed.2018.08.035","article-title":"Sarcopenia, frailty and their prevention by exercise","volume":"132","author":"Nascimento","year":"2019","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"10.1016\/j.clbc.2024.12.016_bib0108","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/j.2040-4603.2019.tb00097.x","article-title":"Physical exercise in the oldest old","volume":"9","author":"Valenzuela","year":"2019","journal-title":"Compr Physiol"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.016_bib0109","first-page":"25","article-title":"Exercise as a remedy for sarcopenia","volume":"17","author":"Landi","year":"2014","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"7","key":"10.1016\/j.clbc.2024.12.016_bib0110","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/14740338.2023.2181338","article-title":"Thromboembolism profiles associated with cyclin-dependent kinase 4\/6 inhibitors: a real-world pharmacovigilance study and a systematic review","volume":"22","author":"Gao","year":"2023","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"10.1016\/j.clbc.2024.12.016_bib0065","doi-asserted-by":"crossref","first-page":"216","DOI":"10.21037\/gs.2018.02.03","article-title":"A high burden of comorbid conditions leads to decreased survival in breast cancer","volume":"7","author":"Woelfel","year":"2018","journal-title":"Gland Surg"},{"issue":"12","key":"10.1016\/j.clbc.2024.12.016_bib0066","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1038\/s41380-020-00865-6","article-title":"Prognostic value of depression and anxiety on breast cancer recurrence and mortality: a systematic review and meta-analysis of 282,203 patients","volume":"25","author":"Wang","year":"2020","journal-title":"Mol Psychiatry"},{"issue":"2","key":"10.1016\/j.clbc.2024.12.016_bib0067","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1200\/JCO.2009.22.5011","article-title":"Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program","volume":"28","author":"Palesh","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.016_bib0068","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/tbj.12355","article-title":"Managing anxiety and depression during treatment","volume":"21","author":"Spiegel","year":"2015","journal-title":"Breast J"},{"issue":"4","key":"10.1016\/j.clbc.2024.12.016_bib0069","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s12609-021-00431-1","article-title":"Health-related suffering and palliative care in breast cancer","volume":"13","author":"Sunilkumar","year":"2021","journal-title":"Curr Breast Cancer Rep"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.016_bib0070","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10549-017-4485-0","article-title":"Keinan-Boker L. Chronic pain and other symptoms among breast cancer survivors: prevalence, predictors, and effects on quality of life","volume":"167","author":"Hamood","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2024.12.016_bib0071","article-title":"Prevalence and severity of pain in cancer patients in Germany","volume":"2","author":"Broemer","year":"2021","journal-title":"Front pain Res (Lausanne, Switzerland)"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.016_bib0072","first-page":"97","article-title":"SEOM clinical guideline for treatment of cancer pain (2017)","volume":"20","author":"Jara","year":"2018","journal-title":"Clin Transl Oncol Off Publ Fed Spanish Oncol Soc Natl Cancer Inst Mex"},{"issue":"5","key":"10.1016\/j.clbc.2024.12.016_bib0073","doi-asserted-by":"crossref","first-page":"e96748","DOI":"10.1371\/journal.pone.0096748","article-title":"Treatment related impairments in arm and shoulder in patients with breast cancer: a systematic review","volume":"9","author":"Hidding","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.clbc.2024.12.016_bib0074","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10147-012-0377-9","article-title":"Frequency of fibromyalgia syndrome in breast cancer patients","volume":"18","author":"Akkaya","year":"2013","journal-title":"Int J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2024.12.016_bib0075","doi-asserted-by":"crossref","first-page":"911","DOI":"10.14740\/jocmr3617w","article-title":"Comparison of comorbid conditions between cancer survivors and age-matched patients without cancer","volume":"10","author":"Roy","year":"2018","journal-title":"J Clin Med Res"},{"issue":"12","key":"10.1016\/j.clbc.2024.12.016_bib0076","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1093\/rheumatology\/keaa166","article-title":"Risks of solid cancers in elderly persons with osteoarthritis or ankylosing spondylitis","volume":"59","author":"Ward","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.clbc.2024.12.016_bib0077","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/1078155215603229","article-title":"Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle","volume":"22","author":"Li","year":"2016","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"issue":"8","key":"10.1016\/j.clbc.2024.12.016_bib0111","doi-asserted-by":"crossref","first-page":"977","DOI":"10.6004\/jnccn.2019.0038","article-title":"Adult cancer pain, version 3.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Swarm","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.clbc.2024.12.016_bib0112","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semarthrit.2014.05.014","article-title":"An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)","volume":"44","author":"Bruy\u00e8re","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clbc.2024.12.016_bib0113","article-title":"Recomendaciones para el seguimiento de las mujeres supervivientes de C\u00e1ncer de Mama","year":"2017","journal-title":"SEOM"},{"key":"10.1016\/j.clbc.2024.12.016_bib0114","unstructured":"Sa\u00fade Sg. Gu\u00eda T\u00e9cnica Del Proceso de Atenci\u00f3n a La Fibromialgia.; 2009. https:\/\/www.sergas.es\/Asistencia-sanitaria\/Documents\/45\/G11Fibro.pdf."},{"issue":"2","key":"10.1016\/j.clbc.2024.12.016_bib0115","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/annrheumdis-2016-209724","article-title":"EULAR revised recommendations for the management of fibromyalgia","volume":"76","author":"Macfarlane","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.clbc.2024.12.016_bib0116","first-page":"472","article-title":"Recomendaciones revisadas de la EULAR para el manejo de la fibromialgia","volume":"43","author":"Alc\u00e1ntara Montero","year":"2017","journal-title":"Med Fam Semer"},{"key":"10.1016\/j.clbc.2024.12.016_sbref0117","series-title":"Handbook of Advanced Cancer Care","article-title":"for Medical Oncology ES","author":"Catane","year":"2006"},{"issue":"3","key":"10.1016\/j.clbc.2024.12.016_bib0118","first-page":"203","article-title":"Manejo y tratamiento del dolor en cuidados paliativos","volume":"13","author":"Torcal Baz","year":"2020","journal-title":"Rev Cl\u00ednica Med Fam"},{"issue":"12","key":"10.1016\/j.clbc.2024.12.016_bib0078","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"17","key":"10.1016\/j.clbc.2024.12.016_bib0079","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176350","article-title":"CDK4\/6 inhibitors in breast cancer treatment: potential interactions with drug, gene, and pathophysiological conditions","volume":"21","author":"Roncato","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clbc.2024.12.016_bib0080","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.thromres.2021.11.009","article-title":"Risk of venous and arterial thromboembolic events in women with advanced breast cancer treated with CDK 4\/6 inhibitors: A systematic review and meta-analysis","volume":"208","author":"Bolzacchini","year":"2021","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.clbc.2024.12.016_bib0081","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/14740338.2021.1981856","article-title":"Association between cyclin-dependent kinase 4\/6 inhibitors and venous thromboembolism: analysis of F.A.E.R.S. data","volume":"21","author":"Yan","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clbc.2024.12.016_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114906","article-title":"Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure","volume":"164","author":"Roncato","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"10.1016\/j.clbc.2024.12.016_bib0083","doi-asserted-by":"crossref","first-page":"e1575","DOI":"10.1002\/cnr2.1575","article-title":"Lactic acidosis, a potential toxicity from drug-drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: a case report","volume":"5","author":"Lagampan","year":"2022","journal-title":"Cancer reports (Hoboken, NJ)"},{"key":"10.1016\/j.clbc.2024.12.016_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102624","article-title":"Estrogen deprivation effects of endocrine therapy in breast cancer patients: incidence, management and outcome","volume":"120","author":"Cucciniello","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.clbc.2024.12.016_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100629","article-title":"Health-related quality of life in breast cancer patients treated with CDK4\/6 inhibitors: a systematic review","volume":"7","author":"Di Lauro","year":"2022","journal-title":"ESMO open"},{"key":"10.1016\/j.clbc.2024.12.016_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115113","article-title":"The journey of patients affected by metastatic hormone receptor-positive\/HER2-negative breast cancer from CDK 4\/6 inhibitors to second-line treatment: a real-world analysis of 701 patients enrolled in the GIM14\/BIOMETA study","volume":"213","author":"Molinelli","year":"2024","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.clbc.2024.12.016_bib0087","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/14737140.2021.1944109","article-title":"The evolution of cyclin dependent kinase inhibitors in the treatment of cancer","volume":"21","author":"Jhaveri","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clbc.2024.12.016_bib0088","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.breast.2020.10.007","article-title":"Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia","volume":"54","author":"Fuentes-Antr\u00e1s","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2024.12.016_bib0089","unstructured":"Pharmacist US. Drug interactions associated with CDK 4\/6 inhibitors. Published 2023. Accessed June 30, 2024. https:\/\/www.uspharmacist.com\/article\/drug-interactions-associated-with-cdk-4-6-inhibitors."},{"key":"10.1016\/j.clbc.2024.12.016_bib0090","unstructured":"National Institute for Health and Care Excellence. Ribociclib interactions. Accessed October 27, 2023. https:\/\/bnf.nice.org.uk\/interactions\/ribociclib\/."},{"issue":"3","key":"10.1016\/j.clbc.2024.12.016_bib0091","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/23993693221114901","article-title":"Serum cystatin C level can be used to estimate GFR in patients with solid tumors: moderator commentary","volume":"6","author":"Vanhoutte","year":"2022","journal-title":"J Onco-Nephrol"},{"key":"10.1016\/j.clbc.2024.12.016_bib0092","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2018.05.017","article-title":"Palbociclib plus endocrine therapy in older women with HR+\/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies","volume":"101","author":"Rugo","year":"2018","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.clbc.2024.12.016_bib0093","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/2042098618772979","article-title":"Evaluating the risk of QTc prolongation associated with antidepressant use in older adults: a review of the evidence","volume":"9","author":"Rochester","year":"2018","journal-title":"Ther Adv drug Saf"},{"key":"10.1016\/j.clbc.2024.12.016_bib0094","first-page":"79","article-title":"CDK 4\/6 inhibitors combined with radiotherapy: a review of literature","volume":"26","author":"Bosacki","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2024.12.016_bib0119","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.recesp.2019.03.017","article-title":"Abordaje de la fibrilaci\u00f3n auricular en pacientes con c\u00e1ncer activo. Documento de consenso de expertos y recomendaciones","volume":"72","author":"L\u00f3pez-Fern\u00e1ndez","year":"2019","journal-title":"Rev Espa\u00f1ola Cardiol"},{"issue":"2","key":"10.1016\/j.clbc.2024.12.016_bib0120","first-page":"171","article-title":"SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)","volume":"22","author":"Mu\u00f1oz Mart\u00edn","year":"2020","journal-title":"Clin Transl Oncol Off Publ Fed Spanish Oncol Soc Natl Cancer Inst Mex"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924003677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924003677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:56:39Z","timestamp":1762548999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820924003677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":120,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1526820924003677"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2024.12.016","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and Management of Medical Comorbidities in Patients With HR+\/HER2\u2013 Metastatic Breast Cancer Treated With CDK4\/6 Inhibitors: Literature Review and Recommendations From Experts in Spain Opinion","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2024.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}